MLYS (Mineralys Therapeutics) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mineralys Therapeutics Days Payable?

Mineralys Therapeutics's average Accounts Payable for the three months ended in Dec. 2024 was $1.79 Mil. Mineralys Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Mineralys Therapeutics's Days Payable or its related term are showing as below:

MLYS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 124.08
* Ranked among companies with meaningful Days Payable only.

Mineralys Therapeutics's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Mineralys Therapeutics Days Payable Historical Data

The historical data trend for Mineralys Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mineralys Therapeutics Days Payable Chart

Mineralys Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Mineralys Therapeutics Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Mineralys Therapeutics's Days Payable

For the Biotechnology subindustry, Mineralys Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mineralys Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Mineralys Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Mineralys Therapeutics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (0.601	+	0.479)	/	2 )	/	0	*	365
=	0.54					/	0	*	365
=	N/A

Mineralys Therapeutics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (3.106	+	0.479)	/	2 )	/	0	*	365 / 4
=	1.7925					/	0	*	365 / 4
=	N/A

Mineralys Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Mineralys Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Mineralys Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mineralys Therapeutics Inc (NAS:MLYS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087

Website

https://mineralystx.com

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Srinivas Akkaraju	director, 10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Jon Congleton	director, officer: Chief Executive Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Adam Scott Levy	officer: CFO, Chief Bus. Off. and Secy.	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
David Malcom Rodman	officer: Chief Medical Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Catalys Pacific Fund, Lp	10 percent owner	301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Hbm Healthcare Investments (cayman) Ltd.	10 percent owner	GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204
Olivier Litzka	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Takeshi Takahashi	director	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Brian Taylor Slingsby	director, 10 percent owner	C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087
Ra Capital Nexus Fund Iii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Alexander Asam	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361